Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML

No views

VJHemOnc – Video Journal of Hematology & HemOnc

52 minutes ago

Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML

Phase I/II study of a quizartinib, venetoclax, & decitabine triplet regimen in FLT3-ITD mutated AML